WAVE Life Sciences (NASDAQ:WVE) Insider Chris Francis Sells 9,375 Shares

WAVE Life Sciences Ltd. (NASDAQ:WVE) insider Chris Francis sold 9,375 shares of the firm’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $16.03, for a total value of $150,281.25. Following the completion of the sale, the insider directly owned 25,000 shares in the company, valued at approximately $400,750. The trade was a 27.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

Chris Francis also recently made the following trade(s):

• On Monday, December 8th, Chris Francis sold 441,031 shares of WAVE Life Sciences stock. The shares were sold at an average price of $14.57, for a total value of $6,425,821.67.

WAVE Life Sciences Stock Performance

WAVE Life Sciences stock opened at $15.15 on Wednesday. The stock has a market capitalization of $2.53 billion, a P/E ratio of -20.20 and a beta of -1.82. The company’s fifty day moving average price is $11.78 and its 200 day moving average price is $9.26. WAVE Life Sciences Ltd. has a 1 year low of $5.28 and a 1 year high of $21.73.

WAVE Life Sciences (NASDAQ:WVE) last posted its quarterly earnings data on Monday, November 10th. The company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.02). The company had revenue of $7.61 million for the quarter, compared to analyst estimates of $9.85 million. WAVE Life Sciences had a negative return on equity of 75.61% and a negative net margin of 111.64%. Sell-side analysts predict that WAVE Life Sciences Ltd. will post -1.14 EPS for the current year.

Wall Street Analysts Forecast Growth

WVE has been the topic of several research analyst reports. Raymond James Financial reiterated an “outperform” rating and issued a $21.00 price objective on shares of WAVE Life Sciences in a report on Monday, December 8th. Weiss Ratings restated a “sell (d-)” rating on shares of WAVE Life Sciences in a research report on Wednesday, October 8th. Truist Financial lifted their price target on WAVE Life Sciences from $36.00 to $50.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. Leerink Partners reissued an “outperform” rating on shares of WAVE Life Sciences in a research note on Monday, December 8th. Finally, Wall Street Zen lowered WAVE Life Sciences from a “hold” rating to a “sell” rating in a report on Saturday. Thirteen investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $31.67.

Institutional Trading of WAVE Life Sciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. Federated Hermes Inc. grew its holdings in shares of WAVE Life Sciences by 678,144.7% in the third quarter. Federated Hermes Inc. now owns 3,750,693 shares of the company’s stock valued at $27,455,000 after purchasing an additional 3,750,140 shares during the period. Adage Capital Partners GP L.L.C. boosted its holdings in WAVE Life Sciences by 20.0% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 15,016,500 shares of the company’s stock valued at $97,607,000 after purchasing an additional 2,500,000 shares during the last quarter. Loomis Sayles & Co. L P grew its stake in shares of WAVE Life Sciences by 35.3% in the 2nd quarter. Loomis Sayles & Co. L P now owns 3,295,700 shares of the company’s stock valued at $21,422,000 after buying an additional 859,160 shares during the period. Stempoint Capital LP grew its stake in shares of WAVE Life Sciences by 902.2% in the 2nd quarter. Stempoint Capital LP now owns 900,338 shares of the company’s stock valued at $5,852,000 after buying an additional 810,505 shares during the period. Finally, Kennedy Capital Management LLC increased its holdings in shares of WAVE Life Sciences by 1,489.5% during the 3rd quarter. Kennedy Capital Management LLC now owns 540,437 shares of the company’s stock worth $3,956,000 after buying an additional 506,437 shares during the last quarter. 89.73% of the stock is owned by institutional investors and hedge funds.

WAVE Life Sciences Company Profile

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.